Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is a clinical-stage gene therapy pioneer developing innovative treatments for ocular and rare diseases through its proprietary intravitreal platform. This resource provides investors and medical professionals with essential updates on the company's clinical trials, regulatory milestones, and strategic initiatives.
Access real-time information about ADVM's AAV-based therapies designed to reduce treatment burdens in conditions like wet AMD. The page aggregates official press releases, partnership announcements, and trial result disclosures - critical data for evaluating the company's progress in advancing durable single-dose therapies.
Key content includes updates on lead candidates like the wet AMD gene therapy program, manufacturing developments, and peer-reviewed research publications. Track progress across therapeutic areas including ophthalmology and rare genetic disorders through verified company communications.
Bookmark this page for streamlined access to ADVM's latest scientific advancements and corporate updates. Check regularly for new developments in their mission to transform chronic disease management through groundbreaking gene therapy approaches.
Adverum Biotechnologies (ADVM) has reported its Q4 and full year 2024 financial results, highlighting significant progress with its Ixo-vec gene therapy for wet AMD treatment. The company has initiated ARTEMIS, their first pivotal trial, which will evaluate Ixo-vec in approximately 284 patients.
The company's cash position stood at $125.7 million as of December 31, 2024, expected to fund operations into H2 2025. Q4 2024 resulted in a net loss of $40.9 million ($1.96 per share), compared to $24.5 million in Q4 2023. R&D expenses increased to $24.1 million from $15.3 million, while G&A expenses rose to $18.5 million from $11.7 million year-over-year.
Key upcoming milestones include the initiation of the global AQUARIUS Phase 3 trial in H2 2025 and presentation of Phase 2 LUNA two-year follow-up data in Q4 2025.
Adverum Biotechnologies (NASDAQ: ADVM) has announced an inducement grant for a new employee under its 2017 Inducement Plan. The Compensation Committee approved non-qualified stock options to purchase 30,000 shares of common stock at an exercise price of $3.83 per share, matching Adverum's closing price on the grant date.
The stock options will vest over a four-year period, with 25% vesting after the first year and the remaining shares vesting monthly at 1/48th over the subsequent 36 months, contingent on the employee's continued service with Adverum. The grant was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in the 2025 RBC Capital Markets Ophthalmology Virtual Conference. The company will engage in a fireside chat scheduled for Thursday, April 3 at 10:45 a.m. ET.
Interested parties can access the webcast through the Events and Presentations section of Adverum's website in the Investors area. The recording will remain available for a minimum of 30 days after the event.
Adverum Biotechnologies (Nasdaq: ADVM) has initiated ARTEMIS, a pioneering Phase 3 study evaluating Ixo-vec, a one-time gene therapy for wet AMD. The US-based trial will assess a single Ixo-vec injection versus aflibercept in 284 patients, including both treatment-naïve and previously treated individuals.
The study's primary endpoint measures change in best corrected visual acuity at one year, with a non-inferiority margin of -4.5 letters. ARTEMIS is the first of two planned Phase 3 registrational trials, with the second study (AQUARIUS) to be conducted globally.
Key trial design features include:
- Single administration of Ixo-vec (6E10 vg/eye) compared to aflibercept (2mg) every 8 weeks
- Three loading doses of aflibercept prior to Ixo-vec administration
- Eligibility for supplemental aflibercept injections
- Prophylactic steroid eye drops for all patients
Adverum Biotechnologies (ADVM) has granted inducement awards to 5 new employees under its 2017 Inducement Plan. The awards include:
- Non-qualified stock options to purchase 44,380 shares at $4.20 per share
- Restricted stock units (RSUs) for 22,790 shares
The stock options will vest over 4 years, with 25% vesting after the first year and the remaining vesting monthly over 36 months. The RSUs will vest over 3 years, with one-third vesting annually. Both awards are contingent on continued employment with Adverum. These grants were approved by the Compensation Committee as inducement material for new employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, announced its upcoming participation in the Cowen 45th Annual Healthcare Life Sciences Conference. The company will present on Tuesday, March 4 at 11:50 a.m. ET.
Investors and interested parties can access a webcast of the presentation through the Events and Presentations section of Adverum's website. A replay will remain available on the site for at least 30 days after the event.
Adverum is working to establish gene therapy as a new standard of care for highly prevalent ocular diseases, positioning this conference appearance as an opportunity for the company to share updates on its clinical progress and pipeline developments.
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on developing gene therapy solutions for common eye diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's presentation is scheduled for Tuesday, February 11, at 4:40 p.m. ET.
Interested parties can access the presentation webcast through the Events and Presentations section in the Investors area of Adverum's website. The presentation recording will remain available for viewing on the company's website for a minimum of 30 days after the event.
Adverum Biotechnologies (ADVM) announced that its Compensation Committee granted inducement awards to 13 new employees on December 4, 2024. The awards include non-qualified stock options to purchase 68,640 shares and restricted stock units (RSUs) for 34,920 shares under the company's 2017 Inducement Plan.
The stock options have an exercise price of $6.00 per share, with a four-year vesting schedule: 25% vesting after one year and the remaining vesting monthly over 36 months. The RSUs will vest over three years, with 33 1/3% vesting annually, subject to continued employment.
Adverum Biotechnologies (ADVM) announced that its Compensation Committee granted an inducement award to a new employee on November 17, 2024. The award consists of non-qualified stock options to purchase 55,000 shares of common stock under the company's 2017 Inducement Plan. The stock options have an exercise price of $6.86 per share, based on the closing price on November 15, 2024. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over 36 months, contingent on continued employment.
Adverum Biotechnologies announced positive 52-week LUNA and 4-year OPTIC trial results for Ixo-vec, their gene therapy treatment for wet AMD. The LUNA trial demonstrated that the 6E10 dose maintained visual and anatomic endpoints with over 80% reduction in injection burden. No patients using local steroid prophylaxis showed inflammation at week 52. The OPTIC trial showed stable therapeutic effects through 4 years with an 86% reduction in annual anti-VEGF injections. The company plans to advance to Phase 3 trials with the ARTEMIS study, expected to initiate in 1H 2025. Patient preference data showed 93% of LUNA participants preferred Ixo-vec over prior treatments.
FAQ
What is the current stock price of Adverum Biotech (ADVM)?
What is the market cap of Adverum Biotech (ADVM)?
